Strategies To Design Selective Histone Deacetylase Inhibitors

Cited by (120)

Items 101–120 of 120

1. BindingDB Entry 50020464: -(2-Aminophenyl)-benzamide Inhibitors of Class I HDAC Enzymes with Antiproliferative and Antifibrotic Activity.
   BindingDB · 2024 · UC San Diego
2. BindingDB Entry 50020288: 2-Substituted 1,5-benzothiazepine-based HDAC inhibitors exert anticancer activities on human solid and acute myeloid leukemia cell lines.
   BindingDB · 2024 · UC San Diego
3. BindingDB Entry 50022172: Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency.
   BindingDB · 2025 · UC San Diego
4. BindingDB Entry 50021347: Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine.
   BindingDB · 2025 · UC San Diego
5. BindingDB Entry 50020003: The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs.
   BindingDB · 2024 · UC San Diego
6. BindingDB Entry 50016065: Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability.
   BindingDB · 2023 · UC San Diego
7. BindingDB Entry 50021404: Hydrazides as Inhibitors of Histone Deacetylases.
   BindingDB · 2025 · UC San Diego
8. BindingDB Entry 50023703: Carboxamide-Bearing Panobinostat Analogues Designed To Interact with E103-D104 at the Cavity Opening of Class I HDAC Isoforms.
   BindingDB · 2026 · UC San Diego
9. BindingDB Entry 50022411: Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer.
   BindingDB · 2025 · UC San Diego
10. BindingDB Entry 50022156: Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases.
    BindingDB · 2025 · UC San Diego
11. BindingDB Entry 50020302: Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer.
    BindingDB · 2024 · UC San Diego
12. BindingDB Entry 50022365: Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer.
    BindingDB · 2025 · UC San Diego
13. BindingDB Entry 50017485: Development of Alkylated Hydrazides as Highly Potent and Selective Class I Histone Deacetylase Inhibitors with T cell Modulatory Properties.
    BindingDB · 2023 · UC San Diego
14. BindingDB Entry 50019324: Evolution of Slow-Binding Inhibitors Targeting Histone Deacetylase Isoforms.
    BindingDB · 2024 · UC San Diego
15. BindingDB Entry 50023386: Hydrazide-Based Class I Selective HDAC Inhibitors Completely Reverse Chemoresistance Synergistically in Platinum-Resistant Solid Cancer Cells.
    BindingDB · 2026 · UC San Diego
16. BindingDB Entry 50021778: Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitors.
    BindingDB · 2025 · UC San Diego
17. BindingDB Entry 50021668: Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.
    BindingDB · 2025 · UC San Diego
18. BindingDB Entry 50022827: Rationally designed febuxostat-based hydroxamic acid and its pH-Responsive nanoformulation elicits anti-tumor activity.
    BindingDB · 2026 · UC San Diego
19. BindingDB Entry 50020376: Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase
    BindingDB · 2024 · UC San Diego
20. Functional Classification of Zn2+-Dependent Histone Deacetylase Homologs and Variants Using Chemical Profiling
    Aleksandra Kopranovic, Hannah Münster, Aaron Rosowski, Louis Groll, Florian Almstätter, Eva Attenhauser, Franz‐Josef Meyer‐Almes · 2026 · International Journal of Molecular Sciences